Role of the Vasodilator Peptide Angiotensin-(1-7) in Cardiovascular Drug Therapy

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2007 Jun 23

PMID 17583183

Citations 48

Authors

Christoph Schindler

Peter Bramlage

Wilhelm Kirch

Carlos M Ferrario

Affiliations

Soon will be listed here.

Abstract

The renin-angiotensin-system (RAS) is a cascade of enzymatic reactions resulting ultimately in the formation of angiotensin II. Recent research has expanded the knowledge about the RAS by adding new components to the pathways: angiotensin-(1-5) [Ang-1-5], angiotensin-(1-7) [Ang-(1-7)], angiotensin-(1-9) [Ang-(1-9)], an ACE homologous enzyme, ACE2, and the G-protein-coupled receptor mas as a molecular receptor for Ang-(1-7). Although previous studies provided some conflicting evidence about the relevance of Ang-(1-7) in the regulation of vascular and renal function, data now demonstrate that Ang-(1-7) contributes to the cardiovascular effects of ACE-inhibitors (ACE-1) and AT1-receptor-blockers (ARBs) both in experimental conditions and in humans. This review summarizes and critically discusses the currently available experimental and clinical study evidence for the role of Ang-(1-7) as a vasodilator and anti-trophic peptide in cardiovascular drug therapy. In addition, the potential therapeutic impact of currently available RAS blocking agents (ACE-1 and ARBs) and new agents still under development (renin-inhibitors) on the RAS-effector peptides is highlighted.

Citing Articles

Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.

Tawengi M, Al-Dali Y, Tawengi A, Benter I, Akhtar S Front Pharmacol. 2024; 15:1394997.

PMID: 39234105 PMC: 11373609. DOI: 10.3389/fphar.2024.1394997.

The Renin-Angiotensin System in Liver Disease.

McGrath M, Wentworth B Int J Mol Sci. 2024; 25(11).

PMID: 38891995 PMC: 11172481. DOI: 10.3390/ijms25115807.

Alternative Renin-Angiotensin System.

Bader M, Steckelings U, Alenina N, Santos R, Ferrario C Hypertension. 2024; 81(5):964-976.

PMID: 38362781 PMC: 11023806. DOI: 10.1161/HYPERTENSIONAHA.123.21364.

Role of Angiotensin Converting Enzyme-2 and its modulation in disease: exploring new frontiers.

Magazine R, Chogtu B, Bhat A Med Pharm Rep. 2023; 96(2):146-153.

PMID: 37197279 PMC: 10184530. DOI: 10.15386/mpr-2345.

Alamandine alleviated heart failure and fibrosis in myocardial infarction mice.

Zhao K, Xu T, Mao Y, Wu X, Hua D, Sheng Y Biol Direct. 2022; 17(1):25.

PMID: 36167556 PMC: 9516792. DOI: 10.1186/s13062-022-00338-6.

References

Porsti I, Bara A, Busse R, Hecker M . Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol. 1994; 111(3):652-4. PMC: 1910086. DOI: 10.1111/j.1476-5381.1994.tb14787.x. View

Meng W, Busija D . Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke. 1993; 24(12):2041-4; discussion 2045. DOI: 10.1161/01.str.24.12.2041. View

Bovy P, Trapani A, McMahon E, Palomo M . A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists. J Med Chem. 1989; 32(3):520-2. DOI: 10.1021/jm00123a002. View

Wilsdorf T, Gainer J, Murphey L, Vaughan D, Brown N . Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension. 2001; 37(4):1136-40. DOI: 10.1161/01.hyp.37.4.1136. View

Stergiou G, Skeva I . Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences. Curr Top Med Chem. 2004; 4(4):473-81. DOI: 10.2174/1568026043451320. View

Metzger R, Bader M, Ludwig T, Berberich C, Bunnemann B, Ganten D . Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett. 1995; 357(1):27-32. DOI: 10.1016/0014-5793(94)01292-9. View

Hall J . The renin-angiotensin system: renal actions and blood pressure regulation. Compr Ther. 1991; 17(5):8-17. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Ren Y, Garvin J, Carretero O . Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002; 39(3):799-802. DOI: 10.1161/hy0302.104673. View

10.

Abbas A, Gorelik G, Carbini L, Scicli A . Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension. 1997; 30(2 Pt 1):217-21. DOI: 10.1161/01.hyp.30.2.217. View

11.

Machado R, Ferreira M, Belo A, Santos R, Andrade S . Vasodilator effect of angiotensin-(1-7) in mature and sponge-induced neovasculature. Regul Pept. 2002; 107(1-3):105-13. DOI: 10.1016/s0167-0115(02)00070-8. View

12.

Ferrario C, Smith R, Brosnihan B, Chappell M, Campese V, Vesterqvist O . Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002; 15(6):557-64. DOI: 10.1016/s0895-7061(02)02268-9. View

13.

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View

14.

Langeveld B, van Gilst W, Tio R, Zijlstra F, Roks A . Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension. 2004; 45(1):138-41. DOI: 10.1161/01.HYP.0000149382.83973.c2. View

15.

Macmahon S, Sharpe N, Gamble G, Clague A, Mhurchu C, Clark T . Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol. 2000; 36(2):438-43. DOI: 10.1016/s0735-1097(00)00736-1. View

16.

Santos R, Brosnihan K, Jacobsen D, DiCorleto P, Ferrario C . Production of angiotensin-(1-7) by human vascular endothelium. Hypertension. 1992; 19(2 Suppl):II56-61. DOI: 10.1161/01.hyp.19.2_suppl.ii56. View

17.

Burnier M, Brunner H . Angiotensin II receptor antagonists. Lancet. 2000; 355(9204):637-45. DOI: 10.1016/s0140-6736(99)10365-9. View

18.

Moritz K, Campbell D, Wintour E . Angiotensin-(1--7) in the ovine fetus. Am J Physiol Regul Integr Comp Physiol. 2001; 280(2):R404-9. DOI: 10.1152/ajpregu.2001.280.2.R404. View

19.

Santos R, Campagnole-Santos M, Baracho N, Fontes M, Silva L, Neves L . Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull. 1994; 35(4):293-8. DOI: 10.1016/0361-9230(94)90104-x. View

20.

Lima C, Paula R, Resende F, Khosla M, Santos R . Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension. 1997; 30(3 Pt 2):542-8. DOI: 10.1161/01.hyp.30.3.542. View